Results 311 to 320 of about 266,823 (339)
Some of the next articles are maybe not open access.
2021
In the current management of ROP, anti-VEGF drugs have a very significant role. These drugs can be used in ROP in different clinical situations: as a primary treatment for posterior ROP, for progressing cases after they have been previously treated either with a laser or with an anti-VEGF drug, and as an adjunct in ROP-related vitreoretinal surgery ...
Andrés Kychenthal, Paola Dorta
openaire +1 more source
In the current management of ROP, anti-VEGF drugs have a very significant role. These drugs can be used in ROP in different clinical situations: as a primary treatment for posterior ROP, for progressing cases after they have been previously treated either with a laser or with an anti-VEGF drug, and as an adjunct in ROP-related vitreoretinal surgery ...
Andrés Kychenthal, Paola Dorta
openaire +1 more source
Therapeutic Anti-VEGF Antibodies
2008Vascular endothelial growth factor (VEGF-A) is a key cytokine in the development of normal blood vessels as well as the development of vessels in tumors and other tissues undergoing abnormal angiogenesis. Here, we review the molecular engineering of two humanized antibodies derived from a common mouse anti-VEGF antibody--bevacizumab, a full-length IgG1
S, Lien, H B, Lowman
openaire +2 more sources
Acta Ophthalmologica, 2014
AbstractThe diabetic macular edema (DME) related to visual loss, results mainly from changes in the affected blood‐retina barrier. VEGF, originally described as vascular permeability factor, is considered not only as a critical stimulus of retinal neovascularization but also as the primary inducer of increased vascular permeability involved in the ...
openaire +1 more source
AbstractThe diabetic macular edema (DME) related to visual loss, results mainly from changes in the affected blood‐retina barrier. VEGF, originally described as vascular permeability factor, is considered not only as a critical stimulus of retinal neovascularization but also as the primary inducer of increased vascular permeability involved in the ...
openaire +1 more source
Anti-VEGF Treatment of Corneal Neovascularization
The Ocular Surface, 2011Vascular endothelial growth factor (VEGF) is an angiogenic factor shown to be a critical secreted cytokine in tumorigenesis and retinal neovascularization (NV). Currently, there are two anti-VEGF agents, pegaptanib and ranizumab, approved by the United States Food and Drug Administration (FDA) for intravitreal use in the treatment of wet age-related ...
Anne M, Keating, Deborah S, Jacobs
openaire +2 more sources
Are Intravitreal Anti-VEGF Antibodies Safe?
Ocular Immunology and Inflammation, 2007In the past two years a major shift has occurred in the treatment paradigm for exudative AMD. Traditional palliative treatments, such as thermal laser photocoagulation and photodynamic treatment, h...
Tongalp H, Tezel, Henry J, Kaplan
openaire +2 more sources
Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets, 2020Background: Corneal neovascularization (CN) is a clue feature of different ocular pathological conditions and can lead to corneal edema and opacification with subsequent vision loss. Vascular endothelial growth factor (VEGF), which plays a key role in new vessels formation, proliferation and migration, was found to be up-regulated in these conditions.
Giannaccare, Giuseppe +6 more
openaire +3 more sources
2009
Purpose: A prospective, interventional pilot study to study the effect of ranibizumab on primary pterygium in respect of time.Methods: Five patients with primary pterygium encroaching onto the cornea received a single subconjunctival injection of ranibizumab (0.3mg) and the pterygium was removed three days, one week, two weeks, one month and two months
openaire +1 more source
Purpose: A prospective, interventional pilot study to study the effect of ranibizumab on primary pterygium in respect of time.Methods: Five patients with primary pterygium encroaching onto the cornea received a single subconjunctival injection of ranibizumab (0.3mg) and the pterygium was removed three days, one week, two weeks, one month and two months
openaire +1 more source
Anti-VEGF and intraocular pressure
British Journal of Ophthalmology, 2011It is with great interest that I read the article by Good and associates1 on sustained elevation of intraocular pressure (IOP) after anti-vascular endothelial growth factor (VEGF) injections. Though several authors have observed raised IOP after intravitreal injections,2–6 this study assumes great importance since the authors have tried to identify ...
openaire +2 more sources
Acta Ophthalmologica, 2012
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source
AbstractPurpose To assess safety and efficacy of intraocular injections of anti‐VEGF in patients with diabetic macular edema (DME)Methods The gold standard for treatment has been laser coagulation. Limitations of this therapy are refractive DME, ischemic diabetic maculopathy and complications after laser application.
openaire +1 more source